Point of Care Molecular Diagnostics Market Size & Trends

The Point of Care Molecular Diagnostics Market grew from USD 2.95 billion in 2024 to USD 3.25 billion in 2025. It is expected to continue growing at a CAGR of 9.73%, reaching USD 5.16 billion by 2030.

Setting the Stage for Point of Care Molecular Diagnostics

Point of care molecular diagnostics has emerged as a cornerstone of modern healthcare delivery, decentralizing test administration and enabling timely clinical decisions at the patient’s location. As infectious disease outbreaks, genetic screening demands, and personalized oncology treatments continue to strain traditional laboratory infrastructures, the ability to perform sensitive assays on portable platforms has shifted from a novelty to an imperative. This report delves into the intricate interplay of technological innovation, regulatory frameworks, and market forces that have elevated point of care molecular tools from benchside prototypes to critical components of everyday practice.

Through meticulous analysis of recent product launches, strategic partnerships, and clinical validation studies, this section establishes the fundamental drivers and constraints shaping the sector. It highlights how miniaturization, digital integration, and cost containment converge to redefine value propositions for healthcare providers, payers, and technology developers. By contextualizing historical milestones alongside emerging trends in assay chemistry and instrument design, we chart a cohesive narrative that equips stakeholders with the strategic insight necessary to navigate the dynamic landscape of point of care molecular diagnostics.

Unprecedented Shifts Redefining the Molecular Diagnostics Landscape

The molecular diagnostics landscape is undergoing transformative shifts characterized by an accelerated pace of innovation and market realignment. Advances in isothermal amplification and digital PCR are redefining assay sensitivity and throughput, while hybridization assays integrate ever more sophisticated microarray and fluorescence in situ hybridization capabilities. Meanwhile, sequencing technologies have transitioned from centralized laboratories to near-patient environments, enabling high-resolution genetic analysis in clinical and field settings.

Concurrently, software platforms designed for data management and interpretation are becoming integral, supporting automated workflows and remote connectivity. Such integration fosters real-time decision support, empowering clinicians and public health officials to act on diagnostic results with unprecedented speed. As regulatory pathways adapt to these novel configurations, competitive dynamics shift in favor of organizations that can demonstrate robust clinical performance alongside seamless usability. Together, these factors are converging to propel point of care molecular diagnostics from peripheral use toward mainstream adoption.

Navigating the Implications of 2025 US Tariffs on Molecular Diagnostics

The imposition of new tariffs in 2025 has introduced a layer of complexity that reverberates across the supply chain for molecular diagnostics. Instruments, often produced in international facilities and assembled across multiple borders, now face elevated import costs that directly affect capital expenditure budgets. Similarly, reagents and kits, which rely on globally sourced enzymes and chemicals, encounter increased unit prices that may translate into higher per-test fees or pressure to localize manufacturing.

Beyond direct cost implications, these trade measures incentivize strategic realignment of sourcing and partnerships. Diagnostic developers are evaluating near-shoring options and forging alliances with domestic suppliers to mitigate tariff exposure. In parallel, distributors are reassessing inventory strategies, balancing the risks of stockouts against the burden of holding costs. Ultimately, the 2025 tariffs are acting as a catalyst for supply chain diversification and operational flexibility, compelling market participants to adopt more resilient and cost-effective models.

Insights Across Product, Technology, Application, End User, and Format Segments

The market architecture for point of care molecular diagnostics can be understood through five critical segmentation lenses that reveal distinct areas of opportunity and challenge. In terms of product type, instruments anchor the ecosystem by providing the hardware foundation, reagents and kits supply the essential biochemical components for assays, and software underpins data analysis and connectivity. When viewed through the lens of technology, the spectrum ranges from hybridization assays such as fluorescence in situ hybridization and microarray platforms, through isothermal amplification methods including loop-mediated amplification, nucleic acid sequence based amplification and recombinase polymerase amplification, to polymerase chain reaction techniques differentiated into digital, quantitative and reverse transcription modalities, and finally to sequencing approaches encompassing next generation and Sanger methods.

The application dimension encompasses critical clinical and research areas, starting with cardiology, extending to genetic testing subdomains like carrier, newborn and prenatal screening, and spanning infectious disease categories that address gastrointestinal, respiratory, sexually transmitted and tropical pathogens. Oncology applications further diversify into liquid biopsy, mutation profiling and targeted oncogene panels. Examining the end user perspective reveals utilization across clinics, diagnostic laboratories, home care settings, hospitals and specialized reference laboratories, each with unique workflow requirements. Finally, format segmentation distinguishes between benchtop instruments suited to fixed facilities, portable devices for decentralized testing, and emerging wearable systems designed for continuous monitoring. Together, these segmentation insights illuminate the nuanced drivers of adoption, investment and regulatory focus.

Regional Dynamics Shaping Point of Care Molecular Diagnostics Growth

Regional dynamics play a pivotal role in shaping the trajectory of point of care molecular diagnostics, with distinct growth patterns and regulatory frameworks emerging across global markets. In the Americas, the combination of advanced healthcare infrastructure and proactive reimbursement policies drives robust uptake, particularly in outpatient and emergency settings where rapid turnaround times yield immediate clinical benefits. Stakeholders leverage economies of scale and established distribution channels to integrate novel platforms into national testing strategies.

In Europe, the Middle East and Africa, diverse regulatory environments and variable healthcare funding models necessitate customized market entry approaches. While established European markets emphasize conformity with stringent CE-marking requirements and prioritize interoperability, emerging economies in the Middle East and Africa are increasingly adopting point of care solutions to expand diagnostic access in resource-constrained settings. Collaborative initiatives between public health agencies and private sector entities are crucial to overcoming logistical challenges and achieving scale.

The Asia-Pacific region is characterized by dynamic demand driven by high population densities and growing investment in local manufacturing capabilities. Governments in key markets incentivize technology transfers and domestic production, fostering a competitive landscape where global and regional players vie for share. Digital health initiatives and telemedicine integration further accelerate adoption, positioning the region as a hotbed of innovation for decentralized molecular testing.

Competitive Landscape Spotlight on Market Leaders and Innovators

A competitive landscape dominated by established diagnostics companies is witnessing new entrants and strategic collaborations aimed at capturing emerging niches. Market leaders with extensive portfolios in molecular platforms and consumables are investing in modular, multi-analyte systems to meet the broad spectrum of clinical needs and maintain their foothold. These incumbents leverage scale to optimize manufacturing processes and negotiate supply agreements, ensuring cost efficiencies that underpin competitive pricing strategies.

At the same time, specialized innovators are focusing on breakthrough assay chemistries and compact form factors to address specific use cases, such as decentralized infectious disease testing or oncology monitoring in ambulatory settings. Partnerships between instrument manufacturers and software developers are creating integrated solutions that streamline end-to-end workflows, from sample preparation to digital result reporting. Additionally, contract research organizations and academic spin-offs contribute to the ecosystem by validating novel biomarkers and co-developing next-generation assays, thus expanding the scope of available diagnostics.

Strategic Imperatives for Leaders to Capitalize on Emerging Opportunities

Industry leaders seeking to secure a competitive advantage must embrace several strategic imperatives that align with evolving market demands. First, investing in flexible, multi-mode platforms capable of accommodating a range of assay types will enhance responsiveness to emerging health threats and diversify revenue streams. Second, forging collaborative alliances across the value chain-from raw material suppliers to clinical end users-can streamline product development, accelerate time to market and reduce supply chain vulnerabilities.

Furthermore, active engagement with regulatory bodies to shape favorable pathways and demonstrate clinical utility will accelerate product approvals and reimbursement. Prioritizing digital integration, including connectivity solutions and artificial intelligence-driven analytics, can elevate diagnostic accuracy and facilitate remote monitoring. Finally, cultivating a skilled workforce through targeted hiring and training programs will ensure that organizations possess the expertise required to innovate and adapt in a rapidly shifting environment. By operationalizing these recommendations, industry participants can capitalize on growth opportunities and solidify their leadership positions.

Rigorous Research Methods Underpinning the Analysis

This analysis synthesizes primary and secondary research methodologies to deliver a comprehensive perspective on the point of care molecular diagnostics market. Secondary data sources include regulatory filings, peer-reviewed publications and publicly disclosed financial reports, which provide foundational insights into technology trends, product pipelines and market dynamics. To validate these findings and gather forward-looking perspectives, in-depth interviews were conducted with key opinion leaders, including clinical laboratory directors, R&D executives and policy advisors.

Quantitative data were triangulated through cross-referencing sales figures, shipment data and reimbursement schedules to ensure accuracy. Qualitative analysis further incorporated case studies of successful technology deployments and failure analyses to extract lessons learned. All data were rigorously reviewed to identify biases and ensure consistency, with multiple rounds of peer review performed to uphold the highest standards of methodological integrity. This multifaceted approach underpins the report’s strategic recommendations and market insights.

Charting the Future of Point of Care Molecular Diagnostics

Point of care molecular diagnostics stands at the cusp of broader mainstream integration, propelled by technological breakthroughs and the imperative for rapid, decentralized testing. The interplay of regulatory evolution, supply chain realignment and digital innovation will continue to shape the competitive terrain and define value propositions. Stakeholders who harness segmentation insights, leverage regional market dynamics and adopt agile operational models are well positioned to navigate forthcoming challenges and capture expansion opportunities.

As the sector evolves, sustained investment in platform versatility, strategic collaborations and workforce development will be essential. By maintaining a proactive stance toward regulatory changes and anticipating shifts in healthcare delivery models, organizations can translate analytical insights into market success. The journey toward ubiquitous, high-performing point of care molecular solutions is underway, and those equipped with robust intelligence and strategic foresight will lead the way.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:

Product Type
- Instruments
- Reagents & Kits
- Software
Technology
- Hybridization Assays
  - FISH
  - Microarray
- Isothermal Amplification
  - LAMP
  - NASBA
  - RPA
- PCR
  - dPCR
  - qPCR
  - RT-PCR
- Sequencing
  - Next Generation Sequencing
  - Sanger Sequencing
Application
- Cardiology
- Genetic Testing
  - Carrier Screening
  - Newborn Screening
  - Prenatal Testing
- Infectious Disease
  - Gastrointestinal Infections
  - Respiratory Infections
  - Sexually Transmitted Infections
  - Tropical Diseases
- Oncology
  - Liquid Biopsy
  - Mutation Profiling
  - Oncogene Panel
End User
- Clinics
- Diagnostic Laboratories
- Home Care Settings
- Hospitals
- Reference Laboratories
Format
- Benchtop
- Portable
- Wearable

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:

Americas
- United States
  - California
  - Texas
  - New York
  - Florida
  - Illinois
  - Pennsylvania
  - Ohio
- Canada
- Mexico
- Brazil
- Argentina
Europe, Middle East & Africa
- United Kingdom
- Germany
- France
- Russia
- Italy
- Spain
- United Arab Emirates
- Saudi Arabia
- South Africa
- Denmark
- Netherlands
- Qatar
- Finland
- Sweden
- Nigeria
- Egypt
- Turkey
- Israel
- Norway
- Poland
- Switzerland
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Indonesia
- Thailand
- Philippines
- Malaysia
- Singapore
- Vietnam
- Taiwan

This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:

Roche Diagnostics International AG
Abbott Laboratories
Cepheid Inc.
bioMérieux SA
Qiagen N.V.
Becton Dickinson and Company
Hologic, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Meridian Bioscience, Inc.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Market Sizing & Forecasting

5. Market Dynamics

6. Market Insights

6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Molecular Diagnostics Market, by Product Type

8.1. Introduction
8.2. Instruments
8.3. Reagents & Kits
8.4. Software

9. Point of Care Molecular Diagnostics Market, by Technology

9.1. Introduction
9.2. Hybridization Assays
9.2.1. FISH
9.2.2. Microarray
9.3. Isothermal Amplification
9.3.1. LAMP
9.3.2. NASBA
9.3.3. RPA
9.4. PCR
9.4.1. dPCR
9.4.2. qPCR
9.4.3. RT-PCR
9.5. Sequencing
9.5.1. Next Generation Sequencing
9.5.2. Sanger Sequencing

10. Point of Care Molecular Diagnostics Market, by Application

10.1. Introduction
10.2. Cardiology
10.3. Genetic Testing
10.3.1. Carrier Screening
10.3.2. Newborn Screening
10.3.3. Prenatal Testing
10.4. Infectious Disease
10.4.1. Gastrointestinal Infections
10.4.2. Respiratory Infections
10.4.3. Sexually Transmitted Infections
10.4.4. Tropical Diseases
10.5. Oncology
10.5.1. Liquid Biopsy
10.5.2. Mutation Profiling
10.5.3. Oncogene Panel

11. Point of Care Molecular Diagnostics Market, by End User

11.1. Introduction
11.2. Clinics
11.3. Diagnostic Laboratories
11.4. Home Care Settings
11.5. Hospitals
11.6. Reference Laboratories

12. Point of Care Molecular Diagnostics Market, by Format

12.1. Introduction
12.2. Benchtop
12.3. Portable
12.4. Wearable

13. Americas Point of Care Molecular Diagnostics Market

13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina

14. Europe, Middle East & Africa Point of Care Molecular Diagnostics Market

14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland

15. Asia-Pacific Point of Care Molecular Diagnostics Market

15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan

16. Competitive Landscape

16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Roche Diagnostics International AG
16.3.2. Abbott Laboratories
16.3.3. Cepheid Inc.
16.3.4. bioMérieux SA
16.3.5. Qiagen N.V.
16.3.6. Becton Dickinson and Company
16.3.7. Hologic, Inc.
16.3.8. Thermo Fisher Scientific Inc.
16.3.9. Siemens Healthineers AG
16.3.10. Meridian Bioscience, Inc.

17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix

List of Figures

FIGURE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET MULTI-CURRENCY
FIGURE 2. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET MULTI-LANGUAGE
FIGURE 3. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2024 VS 2030 (%)
FIGURE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

List of Tables

TABLE 1. POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FISH, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LAMP, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NASBA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RPA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DPCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY QPCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RT-PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GASTROINTESTINAL INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY RESPIRATORY INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TROPICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY MUTATION PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOGENE PANEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY WEARABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 86. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 87. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 88. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 89. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 90. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 91. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 92. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 93. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 94. CANADA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 95. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 97. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 99. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 100. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 101. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 103. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 105. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. MEXICO POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 156. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 159. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 160. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 161. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 162. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 164. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 165. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 166. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. GERMANY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 168. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 170. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 171. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 173. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 174. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 175. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 176. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 177. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 178. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. FRANCE POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 192. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 195. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 196. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 197. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 198. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 200. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 201. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 202. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. ITALY POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 204. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 209. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 210. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 212. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 213. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 214. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. SPAIN POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 252. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 255. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 256. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 257. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 258. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 260. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 261. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 262. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 263. DENMARK POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 275. NETHERLANDS POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 276. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 277. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 278. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 279. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 280. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 281. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2030 (USD MILLION)
TABLE 282. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 283. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY GENETIC TESTING, 2018-2030 (USD MILLION)
TABLE 284. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2030 (USD MILLION)
TABLE 285. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 286. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. QATAR POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY FORMAT, 2018-2030 (USD MILLION)
TABLE 288. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 290. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY HYBRIDIZATION ASSAYS, 2018-2030 (USD MILLION)
TABLE 291. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, 2018-2030 (USD MILLION)
TABLE 292. FINLAND POINT OF CARE MOLECULAR DIAGNOSTICS MARKET SIZE, BY PCR, 2018-2030 (USD MILLION)
TABLE 293. FINLAND POINT OF CARE MOLECULAR DIAGNOSTIC

Samples

LOADING...

Companies Mentioned

The companies profiled in this Point of Care Molecular Diagnostics market report include:

Roche Diagnostics International AG
Abbott Laboratories
Cepheid Inc.
bioMérieux SA
Qiagen N.V.
Becton Dickinson and Company
Hologic, Inc.
Thermo Fisher Scientific Inc.
Siemens Healthineers AG
Meridian Bioscience, Inc.

Table Information

Report Attribute	Details
No. of Pages	198
Published	May 2025
Forecast Period	2025 - 2030
Estimated Market Value ( USD ) in 2025	$ 3.25 Billion
Forecasted Market Value ( USD ) by 2030	$ 5.16 Billion
Compound Annual Growth Rate	9.7%
Regions Covered	Global
No. of Companies Mentioned	11

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3175EUR$3,545USD£2,707GBP €3528EUR$3,939USD£3,008GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3425EUR$3,824USD£2,920GBP €3806EUR$4,249USD£3,244GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€4642EUR$5,183USD£3,957GBP €5158EUR$5,759USD£4,397GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€5618EUR$6,272USD£4,789GBP €6242EUR$6,969USD£5,321GBP

Point of Care Molecular Diagnostics Market by Product Type, Technology, Application, End User, Format - Global Forecast to 2030

Setting the Stage for Point of Care Molecular Diagnostics

Unprecedented Shifts Redefining the Molecular Diagnostics Landscape

Navigating the Implications of 2025 US Tariffs on Molecular Diagnostics

Insights Across Product, Technology, Application, End User, and Format Segments

Regional Dynamics Shaping Point of Care Molecular Diagnostics Growth

Competitive Landscape Spotlight on Market Leaders and Innovators

Strategic Imperatives for Leaders to Capitalize on Emerging Opportunities

Rigorous Research Methods Underpinning the Analysis

Charting the Future of Point of Care Molecular Diagnostics

Market Segmentation & Coverage

Table of Contents

Samples

Companies Mentioned

Table Information

Setting the Stage for Point of Care Molecular Diagnostics

Unprecedented Shifts Redefining the Molecular Diagnostics Landscape

Navigating the Implications of 2025 US Tariffs on Molecular Diagnostics

Insights Across Product, Technology, Application, End User, and Format Segments

Regional Dynamics Shaping Point of Care Molecular Diagnostics Growth

Competitive Landscape Spotlight on Market Leaders and Innovators

Strategic Imperatives for Leaders to Capitalize on Emerging Opportunities

Rigorous Research Methods Underpinning the Analysis

Charting the Future of Point of Care Molecular Diagnostics

Market Segmentation & Coverage

Table of Contents

Samples

Companies Mentioned

Table Information

Related Topics

Related Reports

Point of Care Molecular Diagnostics Market Report by Product and Service, Technology, Application, End User, and Region 2025-2033

Point-Of-Care Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Point of Care (POC) Molecular Diagnostics - Global Strategic Business Report

Point-of-Care Molecular Diagnostics Market Report 2025

Point of Care Molecular Diagnostics Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

About the Market